Dr. Costales on Study of Adjuvant Therapy in Uterine Leiomyosarcoma

Anthony Costales, MD
Published: Friday, May 11, 2018



Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.

This study aimed to characterize the efficacy of adjuvant therapy versus observation in women with early-stage uterine confine leiomyosarcoma following complete resection. This is a rare tumor type, Costales says, so they used the National Cancer Database to gather 1000 patients for evaluation.

Investigators were able to evaluate patients from 3 tumor types—leiomyosarcoma, epithelioid leiomyosarcoma, and myxoid leiomyosarcoma. Patients were then stratified based on adjuvant therapy such as chemotherapy, radiation, chemoradiation, or observation. Statistical software provided by the National Cancer Database was then utilized to analyze particular factors associated with trends of either adjuvant treatment or observation, explains Costales.


Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.

This study aimed to characterize the efficacy of adjuvant therapy versus observation in women with early-stage uterine confine leiomyosarcoma following complete resection. This is a rare tumor type, Costales says, so they used the National Cancer Database to gather 1000 patients for evaluation.

Investigators were able to evaluate patients from 3 tumor types—leiomyosarcoma, epithelioid leiomyosarcoma, and myxoid leiomyosarcoma. Patients were then stratified based on adjuvant therapy such as chemotherapy, radiation, chemoradiation, or observation. Statistical software provided by the National Cancer Database was then utilized to analyze particular factors associated with trends of either adjuvant treatment or observation, explains Costales.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor TypesDec 31, 20181.5
Oncology Briefings™: New Frontiers in the Treatment of MSI High Endometrial CancerDec 31, 20181.0
Publication Bottom Border
Border Publication
x